BIOTRONIK Announces First Enrollment in CRT-Next Study

BIOTRONIKBIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK's CRT-DX technology provides therapy through two ventricular leads and features a floating dipole for complete atrial diagnostics without an additional lead. The study is sponsored by the Italian patient organization 'Associazione Portatori Dispositivi Impiantabili Cardiaci' (Association of Implantable Cardiac Devices Patients, APDIC).

"We are proud to be a volunteer association that has become a promoter of CRT," said Dr. Armando Luisi, president of APDIC. "Regardless of the outcome of the CRT-Next study, the findings will be useful to improve the quality of life of patients who need CRT devices."

As CRT-D patients are exposed to a higher risk of complication compared to other cardiac implantable electronic device (CIED) patients, managing risk is important. The CRT-DX system offers AV-synchronous CRT pacing without a separate atrial lead for patients not requiring atrial pacing. In reducing system complexity by eliminating the atrial lead, the CRT-DX system is designed to lower the risk of lead-related adverse events.

"This study was initiated to respond to a specific patient need: to benefit the most from the therapies available with the least risk of adverse events," reported Dr. Mauro Biffi, chief investigator of the Policlinico Sant'Orsola Malpighi, Bologna, Italy, and coordinator of the study, after implanting the novel CRT-DX system in the first patient in the CRT-Next study. "Each patient receives everything that is needed for clinical improvement while avoiding lead redundancy which can cause unfavorable problems. In Italy, this is the first clinical study in the field of implantable devices that is promoted by a non-profit association working in the interest of patients. The study reflects the solid cooperation that can be established between healthcare professionals when the objectives are clear and aim at improving care and quality of life."

The CRT-Next study is being conducted in twenty Italian centers. It enrolls 640 patients with optimized therapy for heart failure with an indication for the implantation of a CRT device.

"The technology impact for patients with heart failure and indication for a CRT-DX device can be significantly improved with the CRT-NEXT study," said Dr. Gabriele Zanotto, Head of the Unit of Pacing and Electrophysiology at the Mater Salutis Hospital in Legnago, Italy, who recently enrolled his first patient in the study. "The possibility to demonstrate that we can reduce complications in these patients is the essence of this study. We have full confidence in its scientific impact."

About BIOTRONIK

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...